Cardiff Oncology, Inc. (CRDF) Tops Q2 EPS by 2c

Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q2 EPS of ($0.25), $0.02 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $110 thousand versus the consensus estimate of $37.5 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Piper Sandler on Fervo Energy (FRVO): 'Capital Access Supports Potential Upside'